Arena (ARNA) Rivals Mixed Ahead of PDUFA; Volatility Elevated (OREX) (VVUS)
Tweet Send to a Friend
Up)
Ahead of Arena Pharmaceuticals' (Nasdaq: ARNA) PDUFA meeting for proposed weight-loss drug lorcaserin today, rivals are looking mixed.
Pre-market action shows VIVUS (Nasdaq: VVUS) lower while Orexigen (Nasdaq: OREX) is looking about 2.7 percent stronger early.
VIVUS has an FDA meeting in July for its obesity drug Qnexa, while Orexigen is looking for approval of its Contrave drug.
Arena shares more than doubled following a positive FDA panel call on May 10th, while VIVUS and Orexigen have seen similar gains.
Volatility for Orexigen has been above its trailing annual average since April while VIVUS volatility has slowly increased since May.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Pre-market action shows VIVUS (Nasdaq: VVUS) lower while Orexigen (Nasdaq: OREX) is looking about 2.7 percent stronger early.
VIVUS has an FDA meeting in July for its obesity drug Qnexa, while Orexigen is looking for approval of its Contrave drug.
Arena shares more than doubled following a positive FDA panel call on May 10th, while VIVUS and Orexigen have seen similar gains.
Volatility for Orexigen has been above its trailing annual average since April while VIVUS volatility has slowly increased since May.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
- Can AMD (AMD) Shake Off the Goldman Downgrade?
- Like Microsoft (MSFT) Xbox 360 Games? Don't Buy an Xbox One...
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers, Options
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
